BioWest names Charpentier as CFO

BioWest Therapeutics (TSX:BWE) has named Jeff Charpentier as CFO, effective last Monday, succeeding Bruce Schmidt, who has resigned as interim CFO and president, but will continue in his role as corporate secretary and a director. Prior to joining BioWest, Mr. Charpentier held a series of progressively senior CFO roles at several public companies in the [...]

Transition begins Phase 1 study of TT-301

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has dosed the first patient with its TT-301 drug candidate in a Phase 1 clinical study. TT-301 has demonstrated efficacy in preclinical models of rheumatoid arthritis, intra cerebral haemorrhage (ICH) and traumatic brain injury (TBI). The Company said data from the trial are a first step in the development of TT-301 [...]

GeneNews completes deal to bring ColonSentry to China

GeneNews (TSX:GEN) has executed a formal marketing partnership agreement with GeneDiagnostics, a private clinical research and services company in China, to market ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer. Under the accord, GeneDiagnostics has obtained non-exclusive rights to market and sell the ColonSentry test in Shanghai and [...]

Kane gets DispersinB from biotech plants

Kane Biotech (TSX-V:KNE) has confirmed the invention of biotech plants producing DispersinB antibiofilm enzyme, representing a proof of concept for developing bacterial disease-resistant agricultural crops. The Company said DispersinB-expressing plants are resistant to plant pathogens due to their ability to inhibit and disrupt biofilms. In addition, this biotech plant can also be used as a [...]

Ondine to target sinusitis market

Ondine Biopharma (TSX,AIM:OBP) intends to establish a wholly owned subsidiary, Sinuwave Technologies, to develop and commercialize photodisinfection-based products that address the chronic sinusitis market. The company said Sinuwave will license all relevant Ondine intellectual property and know-how for this application, including technology internally developed over the past 10 years and technology obtained in Ondine’s December, [...]

In conversation with Doug Unwin

As CEO of closely held Pacific Therapeutics, Doug Unwin owes much to a two-year course at the Westlink Innovation Network, a non-profit centre of excellence that aims to accelerate the rate of successful commercialization of scientific inventions in Western Canada.  He spent eight months with a venture capital firm, eight months with the tech transfer [...]

Response in $8 million financing with OrbiMed

Response Biomedical (TSX: RBM, OTCBB: RPBF) has signed a subscription agreement for the sale of 13.33 million common shares at a price of 60 cents each to funds affiliated with OrbiMed Advisors. In return, Response has agreed to nominate two representatives of OrbiMed Advisors to serve on its board, provided that OrbiMed continues to hold [...]

Cardiome drug clears European committee

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended marketing approval for Cardiome Pharma’s (TSX:COM; NASDAQ:CRME) vernakalant, an investigational intravenous formulation for the conversion of atrial fibrillation to normal heart rhythm in adults. Granting of marketing authorization by the European Commission is expected later this year and will apply [...]

Helix posts positive pharmacokinetic findings

Helix BioPharma (TSX,FSE:HBP; OTCQX:HXBPF) has released positive Phase 2 pharmacokinetic findings for its topical Interferon Alpha-2b in patients with low-grade cervical lesions. The study showed that the topical cream caused no significant systemic interferon Alpha-2b exposure in patients following cervical application, the company said. “The positive outcome of the pharmacokinetic portion of this Phase 2 [...]

TearLab set to join Russell Microcap Index

TearLab (NASDAQ:TEAR; TSX:TLB) is set to join the Russell Microcap Index when Russell Investments updates its comprehensive set of U.S. and global equity indexes after the close of trading this Friday, according to a preliminary list of additions posted recently on the Russell website. Membership in the Russell Microcap Index, which remains in place for [...]

Next Page »